Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report
Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report
Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report
Submitted by
admin
on March 4, 2017 - 1:59pm
Source:
Fierce Pharma
News Tags:
Celgene
Novartis
Bristol-Myers Squibb
orphan drugs
Revlimid
Headline:
Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report
Do Not Allow Advertisers to Use My Personal information
